ArticleAmerican journal of clinical and experimental immunology2013
Tumor necrosis factor neutralization combined with chemotherapy enhances Mycobacterium tuberculosis clearance and reduces lung pathology.
Article in American journal of clinical and experimental immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- Host-Directed Therapies Based on Protease Inhibitors to ControlMicroorganisms · 2025Review
- Tuberculosis vaccines and therapeutic drug: challenges and future directions.Molecular biomedicine · 2025Review
- Potential of Neuroinflammation-Modulating Strategies in Tuberculous Meningitis: Targeting Microglia.Aging and disease · 2024Review
- Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles.International journal of pharmaceutics · 2022Article
- Recent Advances in Host-Directed Therapies for Tuberculosis and Malaria.Frontiers in cellular and infection microbiology · 2022Review
- Anti-tuberculosis chemotherapy alters TNFR2 expression on CD4+ lymphocytes in both drug-sensitive and -resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time.Molecular medicine (Cambridge, Mass.) · 2021Article
- Host-Directed Therapy as a Novel Treatment Strategy to Overcome Tuberculosis: Targeting Immune Modulation.Antibiotics (Basel, Switzerland) · 2020Review
- GrpE Immunization Protects AgainstFrontiers in immunology · 2020Article
- Opportunities for OvercomingInternational journal of molecular sciences · 2019Review
- Myeloid cell TNFR1 signaling dependent liver injury and inflammation upon BCG infection.Scientific reports · 2019Article
- Transmembrane TNF and Partially TNFR1 Regulate TNFR2 Expression and Control Inflammation in Mycobacterial-Induced Pleurisy.International journal of molecular sciences · 2018Article
- GM-CSF targeted immunomodulation affects host response to M. tuberculosis infection.Scientific reports · 2018Article
- Modulation of Roquin Function in Myeloid Cells ReducesJournal of immunology (Baltimore, Md. : 1950) · 2017Article
- Inhibition of IL-17A by secukinumab shows no evidence of increasedClinical & translational immunology · 2017Article
- Host-Directed Therapeutic Strategies for Tuberculosis.Frontiers in medicine · 2017Review
- Effectiveness of a novel cellular therapy to treat multidrug-resistant tuberculosis.Journal of clinical tuberculosis and other mycobacterial diseases · 2016Article
- Innate myeloid cell TNFR1 mediates first line defence against primary Mycobacterium tuberculosis infection.Scientific reports · 2016Article
- Targeting Batf2 for infectious diseases and cancer.Oncotarget · 2015Article
- Etanercept exacerbates inflammation and pathology in a rabbit model of active pulmonary tuberculosis.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2014Article
- Reflections on the immunology of tuberculosis: will we ever unravel the skein?BMC infectious diseases · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) is a major health problem requiring sustained immunity to inhibit Mycobacterium tuberculosis growth and appropriate antimicrobial therapy to prevent dissemination and drug resistance. Cell-mediated immune responses to M. tuberculosis involve the activation of cytokines such as Tumor Necrosis Factor (TNF) which is critical for granuloma formation and host resistance against TB. TNF inhibition, used as therapy for the treatment of inflammatory diseases, disrupts granuloma allowing replication of mycobacteria which may increase the efficacy of TB chemotherapy. To test this hypothesis mice infected with M. tuberculosis were treated with isoniazid (INH) and rifampicin (RMP) in the presence or absence of Enbrel, a soluble TNF receptor antagonist during three phases of M. tuberculosis infection. Inhibition of TNF with Enbrel augmented the efficacy of TB chemotherapy as shown by enhanced mycobacterial clearance from the lung of acute and established infection as well as in chronically infected mice. Furthermore, TNF inhibition significantly reduced lung pathology as compared to TB chemotherapy alone. Therefore, the experimental data suggest that TB chemotherapy may be more effective in the presence of a TNF inhibitor, which may be relevant to eradicate mycobacteria during chronic M. tuberculosis infection or reactivation.
Indexed as
Identifiers
23885330PMC3714199W212634342What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.